The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.q

Pulmonary nodulosis

Publications

Zamora FD, Podgaetz E, Dincer HE

Counterintuitive Pulmonary Nodules in Rheumatoid Arthritis.

Archivos de bronconeumologia. 2016;52(6):334-5

Díez Piña JM, Vázquez Gómez O, Mayoralas Alises S, García Jiménez JD, Alvaro Alvarez D, Rodríguez Bolado MP

[Etanercept as a possible trigger of fatal pulmonary fibrosis].

Archivos de bronconeumologia. 2008;44(7):393-5

Watson P, Simler N, Screaton N, Lillicrap M

Management of accelerated pulmonary nodulosis following etanercept therapy in a patient with rheumatoid arthritis.

Rheumatology (Oxford, England). 2008;47(6):928-9

van Ede A, den Broeder A, Wagenaar M, van Riel P, Creemers MC

Etanercept-related extensive pulmonary nodulosis in a patient with rheumatoid arthritis.

The Journal of rheumatology. 2007;34(7):1590-2

Cunnane G, Warnock M, Fye KH, Daikh DI

Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis.

Arthritis and rheumatism. 2002;47(4):445-9